), his exercise tolerance improved and imaging after 4 cycles demonstrated a partial response. Unfortunately, he was admitted to hospital with pneumonia after his third cycle of maintenance pemetrexed (500 mg/m 2 ) and died 4 days later. Case 2, a 65-year-old Caucasian female presenting with acute onset shortness of breath. Performance status was 0, with no significant past medical history and 20 pack year smoking history. Imaging showed a right lower lobe pulmonary embolism with incidental right upper lobe mass, right lung metastases, and extensive subcarinal, mediastinal, and retroperitoneal lymphadenopathy. Mediastinal biopsy confirmed poorly differentiated adenocarcinoma (TTF+, CK7+, and CK20−). EGFR mutation analysis reported the same exon 20 missense mutation described in case 1.
She had six cycles of pemetrexed (500 mg/m 2 ) and cisplatin (70 mg/m 2 ) chemotherapy with a good partial response. Within 2 months of commencing treatment with maintenance erlotinib (150 mg daily), imaging showed progression of all lesions. Despite early disease stabilization on switching to oral vinorelbine (60 mg/m 2 ), computed tomography scan after 4 months revealed further progression. She was unfit for further treatment and died 2 months later. A number of rare EGFR mutations exist to which response to targeted therapy is unclear. The exon 20 missense mutation S768I is one of these. In Asian populations, prevalence of this mutation is less than 5% although it is more commonly seen in combination with other mutations. 2 In our region, prevalence of this single mutation is 1.5% (unpublished data).
In vitro, cells expressing S768I mutation are less sensitive to EGFRtargeted treatment than wild-type cells. 3 However, reports of clinical outcome in these patients are conflicting. 4, 5 Our two cases add to the evidence that the S768I mutation causes insensitivity to TKI therapy. However, both cases did show response to platinum-based chemotherapy. Furthermore, these cases continue to highlight the importance of publishing treatment response data for cases of rare EGFR mutant lung cancers to guide clinical decision making. lung cancer (NSCLC), the clinical course of patients with NSCLC with HRAS mutations has not been described. The following case discusses a patient with an HRASpositive adenocarcinoma of the lung who experienced rapid clinical decline.
CASE PRESENTATION
A 79-year-old male former smoker with a history of resected World Health Organisation (WHO) Grade I sphenoid meningioma presented to the emergency room, whereupon a computed tomography chest showed a 3-cm soft-tissue density in the anterior segment of the right upper lobes (Figs. 1 and 2). Moderately differentiated adenocarcinoma was confirmed by computed tomography-guided biopsy of the mass.
In September 2010, the patient underwent mediastinoscopy followed by right upper lobectomy. Final pathologic staging was T2aN0M0 (stage Ib) adenocarcinoma, large-cell subtype.
The patient was treated with four cycles of pemetrexed and carboplatin.
In July 2011, 10 months after completing the right upper lobectomy, the disease had metastasized to his brain. He underwent craniotomy for the left temporal lobe mass, followed by stereotactic radiosurgery of additional CNS lesions. Pathology of the temporal lobe lesion revealed poorly differentiated adenocarcinoma consistent with metastasis from a lung primary (Fig. 3) . Multiplex polymerase chain reaction/mass spectroscopy (MassARRAY system) was performed, testing for 647 known gene mutations in solid tumors (among 53 genes), and revealed one mutation, HRAS Q61L ( Table 1 ). The patient's previously resected meningioma was also tested for mutations using the same multiplex polymerase chain reaction/mass spectroscopy platform previously described, and no mutations were found in the meningioma, including no HRAS mutations.
Additional imaging revealed metastatic multiple bony lesions and innumerable liver lesions and bilateral adrenal lesions. The patient had an Eastern Cooperative Oncology Group performance status of three and was not a candidate for systemic palliative chemotherapy. The patient died in January 2012.
DISCUSSION
The case demonstrates a patient diagnosed with adenocarcinoma with HRAS mutation. The patient had a rapid progression from stage IB disease to metastatic adenocarcinoma and death.
Ras mutations are detectable in approximately 20% of lung cancers, with KRAS mutations representing 90% of those mutations. KRAS mutations are associated with a poor overall prognosis 1 in NSCLC. HRAS mutations have been documented in various cancer types (including cervical, salivary gland carcinoma, head and neck squamous cell carcinoma, melanoma, transitional cell carcinoma of the bladder, prostate adenocarcinoma, breast, and both softtissue and osteosarcomas).
2,3 HRAS mutations have also been described in Costello syndrome, also known as faciocutaneoskeletal syndrome, a rare genetic disorder characterized by mental retardation, cardiac abnormalities, and distinct facial features. 4 HRAS mutations represent 1% of all mutations in NSCLC. 5 Although infrequent, the role of HRAS in the pathogenesis of NSCLC is uncertain. Our patient with HRAS mutation had rapid progression from early stage NSCLC and died from metastatic disease less than 18 months after diagnosis. Additional cases with HRAS mutation are needed to evaluate the clinical behavior and prognostic features of HRAS mutant NSCLC. For this patient, the possibility of HRAS mutant NSCLC causing rapid disease progression and death from metastatic NSCLC raises the likelihood that HRAS mutations in NSCLC tumors are aggressive and associated with poor overall prognosis, similar to KRAS mutant NSCLC. Further research and description of clinical cases are needed for improved understanding of this genetic mutation in NSCLC. 
CASES PRESENTATION
In July of 2012, an Asian, 52-year-old male smoker presented with a right cervical lymph node. A stage IV adenocarcinoma in the right lung; lymphangitis carcinomatosis; mediastinal, cervical, and susclavicular lymph nodes; and sacrum and hip bone osteoblastic metastases were diagnosed. Two-point mutations in exon 18 of the EGFR, p.I706T, and p.G719A were detected. Gefitinib treatment started in August of 2012. After 3 months, computed tomography -scan showed a partial response (Fig. 1) .The clinical response was maintained under gefitinib treatment with 22 months of follow up.
The second patient was a Caucasian, 58-year-old female smoker, referred in February of 2013. A stage IV lung adenocarcinoma, in the lower right lobe, with mediastinal lymph nodes as well as cerebral and right adrenal gland metastases was diagnosed. Twopoint mutations in exon 18, p.E709K and p.G719A, were detected. Erlotinib treatment and whole brain radiotherapy began. After 2 months, the patient's performance status improved and computed tomography scan demonstrated a partial response on brain metastases and primary tumor. Then she presented with a progression of extracerebral metastases. Erlotinib was stopped. A chemotherapy combining cisplatin and pemetrexed was administered. In September of 2013, due to disease progression, carboplatin and paclitaxel were proposed. The patient presented a stable disease for 4 months and then progressed. She died 11 months after diagnosis of metastatic disease.
DISCUSSION
The clinical significance of EGFR complex mutations differs whether complex mutations include the most frequent mutations or not. Hata et al 5 showed that tumours with complex mutations, including deletion of exon 19 or L858R point mutation, had the same response rate to EGFR-TKI than those with the same mutations alone. Wu et al 2 showed that patients with rare and complex mutations, compared with patients with classic or rare mutation alone or classic mutation with rare mutations, had a worse response rate to EGFR-TKI (25% versus 74.8, 68.8, and 80%, respectively) and a poorer progressionfree survival (1.4 versus 11.9, 8.1, and 8.0 months). Beau-Faller et al 6 showed that EGFR-TKI efficacy was similar or slightly poorer in patients with complex mutations including p.G719X. Keam et al 3 reported only two double mutations in exon 18, including the G719A + I706T, in a series of 306 patients. The overall survival of this patient, treated with erlotinib, was 53 months. 3 This is the first description of the p.E709K + p.G719A mutation.
To date, the behavior of these NSCLCs with complex mutations are not completely understood. The report of these rare and complex mutations and their response to EGFR-TKI should be very useful for the constitution of wellannotated databases and to improve the knowledge of their specific response to EGFR-TKI. In non-small-cell lung cancer (NSCLC) besides the common exons 19 and 21 EGFR-activating mutations (>90%), exon 18-point mutations (mainly p.G719X) are rare (4%). 1 They are associated with a favorable response rate to EGFR tyrosine kinase inhibitors (EGFR-TKI), 2, 3 but are lower than common mutations. 4 More than one mutation per sample represents complex mutations. Their clinical significance is uncertain, because they are rare (3.4-6.9%).
2,3 Here, we present two cases of NSCLC with rare complex mutation that respond differently to EGFR-TKI.
